Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study
Introduction The real-world virological efficacy and safety of interferon-free direct-acting antiviral (DAA) therapy with ledipasvir (LDV) plus sofosbuvir (SOF) were assessed in patients who were chronically infected with hepatitis C virus (HCV) genotype 2. Methods A total of 126 patients with chronic hepatitis C due to HCV genotype 2 infection who were treated with the LDV/SOF regimen were enrolled. The sustained virological response (SVR) rate and safety were analyzed. SVR was assessed in the intention-to-treat (ITT) population as well as in the modified intention-to-treat (mITT) population, which excluded patients with non-virological failure, including those who dropped out before the SVR assessment. Results The overall SVR rates of the ITT and mITT populations were 87.3% (95% confidence interval [CI] 80.2–92.6) (110/126) and 97.3% (95% CI 92.4–99.4) (110/113), respectively. In the mITT population, the percentages of patients with undetectable HCV RNA at 4, 8, and 12 weeks after the start of therapy were 92.9% (95% CI 86.5–96.9) (105/113), 99.1% (95% CI 95.2–100.0) (112/113), and 100.0% (95% CI 97.4–100.0) (113/113), respectively. Subgroup analyses of the mITT population showed no significant differences in SVR rates according to age, sex, HCV genotype (subtype), history of interferon-based therapy, baseline FIB-4 index, or baseline estimated glomerular filtration rate. In all subpopulations, the SVR rates were > 90%. There were no severe adverse events associated with the treatment. Conclusion The LDV/SOF regimen showed high virological efficacy and acceptable safety in patients with HCV genotype 2 infection. Trial Registration UMIN registration no. 000038604..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
---|---|
Enthalten in: |
Infectious diseases and therapy - 10(2020), 1 vom: 03. Nov., Seite 269-280 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tada, Toshifumi [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Genotype 2 |
---|
Anmerkungen: |
© The Author(s) 2020 |
---|
doi: |
10.1007/s40121-020-00364-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2124347810 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2124347810 | ||
003 | DE-627 | ||
005 | 20240409071152.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230505s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s40121-020-00364-9 |2 doi | |
035 | |a (DE-627)OLC2124347810 | ||
035 | |a (DE-He213)s40121-020-00364-9-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
100 | 1 | |a Tada, Toshifumi |e verfasserin |0 (orcid)0000-0002-0976-6761 |4 aut | |
245 | 1 | 0 | |a Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2020 | ||
520 | |a Introduction The real-world virological efficacy and safety of interferon-free direct-acting antiviral (DAA) therapy with ledipasvir (LDV) plus sofosbuvir (SOF) were assessed in patients who were chronically infected with hepatitis C virus (HCV) genotype 2. Methods A total of 126 patients with chronic hepatitis C due to HCV genotype 2 infection who were treated with the LDV/SOF regimen were enrolled. The sustained virological response (SVR) rate and safety were analyzed. SVR was assessed in the intention-to-treat (ITT) population as well as in the modified intention-to-treat (mITT) population, which excluded patients with non-virological failure, including those who dropped out before the SVR assessment. Results The overall SVR rates of the ITT and mITT populations were 87.3% (95% confidence interval [CI] 80.2–92.6) (110/126) and 97.3% (95% CI 92.4–99.4) (110/113), respectively. In the mITT population, the percentages of patients with undetectable HCV RNA at 4, 8, and 12 weeks after the start of therapy were 92.9% (95% CI 86.5–96.9) (105/113), 99.1% (95% CI 95.2–100.0) (112/113), and 100.0% (95% CI 97.4–100.0) (113/113), respectively. Subgroup analyses of the mITT population showed no significant differences in SVR rates according to age, sex, HCV genotype (subtype), history of interferon-based therapy, baseline FIB-4 index, or baseline estimated glomerular filtration rate. In all subpopulations, the SVR rates were > 90%. There were no severe adverse events associated with the treatment. Conclusion The LDV/SOF regimen showed high virological efficacy and acceptable safety in patients with HCV genotype 2 infection. Trial Registration UMIN registration no. 000038604. | ||
650 | 4 | |a Genotype 2 | |
650 | 4 | |a Hepatitis C virus | |
650 | 4 | |a Ledipasvir | |
650 | 4 | |a Sofosbuvir | |
650 | 4 | |a Sustained virological response | |
700 | 1 | |a Kumada, Takashi |4 aut | |
700 | 1 | |a Okushin, Hiroaki |4 aut | |
700 | 1 | |a Tani, Joji |4 aut | |
700 | 1 | |a Takaguchi, Koichi |4 aut | |
700 | 1 | |a Tsutsui, Akemi |4 aut | |
700 | 1 | |a Toyoda, Hidenori |4 aut | |
700 | 1 | |a Yasuda, Satoshi |4 aut | |
700 | 1 | |a Dohmen, Kazufumi |4 aut | |
700 | 1 | |a Hiraoka, Atsushi |4 aut | |
700 | 1 | |a Michitaka, Kojiro |4 aut | |
700 | 1 | |a Nouso, Kazuhiro |4 aut | |
700 | 1 | |a Kariyama, Kazuya |4 aut | |
700 | 1 | |a Kim, Soo Ryang |4 aut | |
700 | 1 | |a Kim, Soo Ki |4 aut | |
700 | 1 | |a Fujioka, Shinichi |4 aut | |
700 | 1 | |a Mikami, Shigeru |4 aut | |
700 | 1 | |a Watanabe, Yuto |4 aut | |
700 | 1 | |a Tamai, Tsutomu |4 aut | |
700 | 1 | |a Atsukawa, Masanori |4 aut | |
700 | 1 | |a Itokawa, Norio |4 aut | |
700 | 1 | |a Tanaka, Hironori |4 aut | |
700 | 1 | |a Tsuji, Kunihiko |4 aut | |
700 | 1 | |a Ishikawa, Toru |4 aut | |
700 | 1 | |a Imai, Michitaka |4 aut | |
700 | 1 | |a Itobayashi, Ei |4 aut | |
700 | 1 | |a Shibata, Hiroshi |4 aut | |
700 | 1 | |a Shimada, Noritomo |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d Springer Healthcare, 2012 |g 10(2020), 1 vom: 03. Nov., Seite 269-280 |h Online-Ressource |w (DE-627)735690766 |w (DE-600)2701611-0 |w (DE-576)378497367 |x 2193-6382 |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2020 |g number:1 |g day:03 |g month:11 |g pages:269-280 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40121-020-00364-9 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 10 |j 2020 |e 1 |b 03 |c 11 |h 269-280 |